IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research Center
IGC PharmaIGC Pharma(US:IGC) Accessnewswire·2026-02-09 13:30
  • Adds world renowned GNA site to broaden genetic diversity and strengthen path toward 2026 data catalyst - POTOMAC, MARYLAND / ACCESS Newswire / February 9, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced the expansion of its Phase 2 CALMA trial for IGC-AD1 into Colombia, South America, through the addition of Grupo de Neurociencias de Antioquia ("GNA"). This expansion marks a pivotal operational milestone as IGC enters a region internationally recognized for its unique ...
IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research Center - Reportify